IL263574A - Calr and jak2 vaccine compositions - Google Patents

Calr and jak2 vaccine compositions

Info

Publication number
IL263574A
IL263574A IL263574A IL26357418A IL263574A IL 263574 A IL263574 A IL 263574A IL 263574 A IL263574 A IL 263574A IL 26357418 A IL26357418 A IL 26357418A IL 263574 A IL263574 A IL 263574A
Authority
IL
Israel
Prior art keywords
calr
jak2
preparations
jak2 preparations
Prior art date
Application number
IL263574A
Other languages
English (en)
Hebrew (he)
Inventor
Hald Andersen Mads
Orebo Holmstrom Morten
HASSELBALCH Hans
Original Assignee
Hald Andersen Mads
Io Biotech Aps
Orebo Holmstrom Morten
HASSELBALCH Hans
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hald Andersen Mads, Io Biotech Aps, Orebo Holmstrom Morten, HASSELBALCH Hans filed Critical Hald Andersen Mads
Publication of IL263574A publication Critical patent/IL263574A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57426—Specifically defined cancers leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4244—Enzymes
    • A61K40/4251—Kinases, e.g. Raf or Src
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IL263574A 2016-06-10 2018-12-09 Calr and jak2 vaccine compositions IL263574A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA201670417 2016-06-10
PCT/DK2017/050190 WO2017211371A2 (en) 2016-06-10 2017-06-09 Calr and jak2 vaccine compositions

Publications (1)

Publication Number Publication Date
IL263574A true IL263574A (en) 2019-01-31

Family

ID=59284957

Family Applications (1)

Application Number Title Priority Date Filing Date
IL263574A IL263574A (en) 2016-06-10 2018-12-09 Calr and jak2 vaccine compositions

Country Status (8)

Country Link
US (1) US20190328857A1 (enExample)
EP (1) EP3468585A2 (enExample)
JP (1) JP2019517544A (enExample)
CN (1) CN109803674A (enExample)
AU (1) AU2017276498A1 (enExample)
CA (1) CA3026572A1 (enExample)
IL (1) IL263574A (enExample)
WO (1) WO2017211371A2 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019196088A1 (en) * 2018-04-13 2019-10-17 Syz Cell Therapy Co. Methods of obtaining tumor-specific t cell receptors
KR20220088699A (ko) 2019-09-27 2022-06-28 디스크 메디슨, 인크. 골수섬유증 및 관련 상태의 치료 방법
EP4061405A1 (en) * 2019-11-18 2022-09-28 Janssen Biotech, Inc. Vaccines based on mutant calr and jak2 and their uses
CN111087448A (zh) * 2019-12-23 2020-05-01 维塔恩(广州)医药有限公司 肿瘤相关基因jak2突变相关抗原短肽及其应用
EP4121081A4 (en) * 2020-03-17 2024-04-17 Memorial Sloan Kettering Cancer Center VACCINES AGAINST HETEROCLITIC CANCER
CN115380079B (zh) 2020-04-15 2025-04-25 3M创新有限公司 可堆肥组合物、可堆肥制品以及制备可堆肥制品的方法
KR20230012539A (ko) 2020-05-13 2023-01-26 디스크 메디슨, 인크. 골수섬유증을 치료하기 위한 항-헤모주벨린 (hjv) 항체
CN112168829B (zh) * 2020-09-24 2022-02-15 华南理工大学 抗病毒药物在制备治疗骨髓增生异常综合征药物中的应用及制得的骨髓增生异常综合征药物
WO2022216574A1 (en) * 2021-04-05 2022-10-13 Janssen Biotech, Inc. Calr and jak2 t-cell receptors
CA3242956A1 (en) * 2021-12-16 2023-06-22 Janssen Biotech Inc Vaccines based on mutant calr and jak2 and their uses
US20250352627A1 (en) * 2022-06-17 2025-11-20 Ichan School Of Medicine At Mount Sinai Mutant calr-peptide based vaccine

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US58767A (en) 1866-10-16 John brougjbton
US5554372A (en) 1986-09-22 1996-09-10 Emory University Methods and vaccines comprising surface-active copolymers
EP0832231A2 (en) * 1995-06-05 1998-04-01 Incyte Pharmaceuticals, Inc. A C5a-LIKE SEVEN TRANSMEMBRANE RECEPTOR
US6096313A (en) 1996-02-09 2000-08-01 Ludwig Institute For Cancer Research Compositions containing immunogenic molecules and granulocyte-macrophage colony stimulating factor, as an adjuvant
FR2877013A1 (fr) * 2004-10-27 2006-04-28 Assist Publ Hopitaux De Paris Indentification d'une mutation de jak2 impliquee dans la polyglobulie de vaquez
WO2007047653A2 (en) * 2005-10-17 2007-04-26 Sloan-Kettering Institute For Cancer Research Synthetic hla binding peptide analogues of mutant v617f jak2 enzyme and uses therefor
HUE037973T2 (hu) 2008-04-17 2018-09-28 Io Biotech Aps Indolamin-2,3-dioxigenáz-alapú immunterápia
BR112014009526B8 (pt) 2011-10-17 2023-01-17 Herlev Hospital Composição de vacina compreendendo pd-l1, kit de partes compreendendo tal composição e uso dos mesmos para tratar ou prevenir câncer
US9567641B2 (en) * 2013-07-03 2017-02-14 Samsung Electronics Co., Ltd. Combination therapy for the treatment of cancer using an anti-C-met antibody
MX348980B (es) * 2013-09-16 2017-07-05 Cemm-Forschungszentrum Für Molekulare Medizin Gmbh Calreticulina mutante para la diagnosis de malignidades mieloides.
US20170269092A1 (en) * 2014-12-02 2017-09-21 Cemm - Forschungszentrum Fuer Molekulare Medizin Gmbh Anti-mutant calreticulin antibodies and their use in the diagnosis and therapy of myeloid malignancies
CN104561287A (zh) * 2014-12-26 2015-04-29 南京艾迪康医学检验所有限公司 检测calr基因第9外显子突变的试剂和方法
CN105441562A (zh) * 2015-12-31 2016-03-30 德赛诊断系统(上海)有限公司 Carl基因缺失、插入突变的检测方法及试剂盒

Also Published As

Publication number Publication date
EP3468585A2 (en) 2019-04-17
CA3026572A1 (en) 2017-12-14
AU2017276498A1 (en) 2019-01-03
US20190328857A1 (en) 2019-10-31
WO2017211371A3 (en) 2018-01-18
JP2019517544A (ja) 2019-06-24
CN109803674A (zh) 2019-05-24
WO2017211371A2 (en) 2017-12-14

Similar Documents

Publication Publication Date Title
IL279897A (en) Fusosome compositions and uses thereof
IL281863A (en) Pharmaceutical compositions comprising meloxicam
IL263574A (en) Calr and jak2 vaccine compositions
IL272514A (en) Compositions and methods for modifying genomes
IL272089B1 (en) Compounds, compositions and methods
HUE053737T2 (hu) Piridopirrolokinoxalin vegyületek, készítményeik és alkalmazásaik
IL268684A (en) Compositions and methods for immunooncology
IL256652A (en) Therapeutic compositions, combinations, and methods of use
IL262751A (en) Pharmaceutical compositions with enhanced permeation
HUE061247T2 (hu) Termékek és készítmények
HUE056677T2 (hu) Anti-tim-3 ellenanyagok és készítmények
CL2018000813A1 (es) Conjugados de anticuerpo-fármaco de pirrolobenzodiazepina y métodos de uso.
IL256260B (en) Treprostinil derivatives and compositions and uses thereof
EP3411412A4 (en) FIT-IMMUNOGLOBULIN TECHNOLOGY AND USES THEREOF
EP3344263A4 (en) CANCER ANTIGEN TARGETS AND USES THEREOF
IL258259A (en) Adjunctive therapy with 25-hydroxyvitamin d and articles therefor
IL256939B (en) Rapid-acting insulin compositions
EP3481952A4 (en) METHYLATION MARKERS IN THE TREATMENT OF LEUKEMIA AND USES THEREOF
DK3490988T3 (da) Ny forbindelse og fremgangsmåde
HUE054096T2 (hu) Krémesítõ készítmény
EP3424940A4 (en) Radiolabeled drug
HUE060805T2 (hu) Piridinamin-piridon és pirimidinamin-piridon vegyületek
HUE055231T2 (hu) Inzulint tartalmazó gyógyászati készítmények
EP3429689A4 (en) AZELLULAR PLAZENTAPRÄPARATE
DK3463345T3 (da) Farmaceutiske kombinationer